These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 26694594)
21. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Hofmann C; Penner U; Dorow R; Pertz HH; Jähnichen S; Horowski R; Latté KP; Palla D; Schurad B Clin Neuropharmacol; 2006; 29(2):80-6. PubMed ID: 16614540 [TBL] [Abstract][Full Text] [Related]
22. Bisphosphonates and risk of cardiovascular events: a meta-analysis. Kim DH; Rogers JR; Fulchino LA; Kim CA; Solomon DH; Kim SC PLoS One; 2015; 10(4):e0122646. PubMed ID: 25884398 [TBL] [Abstract][Full Text] [Related]
23. Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database. Pazianas M; Clark EM; Eiken PA; Brixen K; Abrahamsen B J Bone Miner Res; 2013 Mar; 28(3):455-63. PubMed ID: 23044864 [TBL] [Abstract][Full Text] [Related]
24. Bisphosphonates use and risk of gastric cancer: an updated meta-analysis of cohort and case-control studies. Cai D; Qin J; Chen G; Feng W; Liu J Minerva Med; 2017 Oct; 108(5):464-472. PubMed ID: 28466630 [TBL] [Abstract][Full Text] [Related]
25. The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. Solomon DH; Hochberg MC; Mogun H; Schneeweiss S Osteoporos Int; 2009 Jun; 20(6):895-901. PubMed ID: 18843515 [TBL] [Abstract][Full Text] [Related]
26. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data. Vinogradova Y; Coupland C; Hippisley-Cox J BMJ; 2013 Jan; 346():f114. PubMed ID: 23325866 [TBL] [Abstract][Full Text] [Related]
27. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. John Camm A Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982 [TBL] [Abstract][Full Text] [Related]
28. Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: a retrospective multi-hospital-based study of 87 Italian cases. Di Fede O; Fusco V; Matranga D; Solazzo L; Gabriele M; Gaeta GM; Favia G; Sprini D; Peluso F; Colella G; Vescovi P; Campisi G Eur J Intern Med; 2013 Dec; 24(8):784-90. PubMed ID: 23768563 [TBL] [Abstract][Full Text] [Related]
29. A Quantitative Analysis of FDA Adverse Event Reports with Oral Bisphosphonates and Clostridium difficile. McConeghy KW; Soriano MM; Danziger LH Pharmacotherapy; 2016 Oct; 36(10):1095-1101. PubMed ID: 27582058 [TBL] [Abstract][Full Text] [Related]
30. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. Kunchur R; Need A; Hughes T; Goss A J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200 [TBL] [Abstract][Full Text] [Related]
31. Oral bisphosphonates and upper gastrointestinal toxicity: a study of cancer and early signals of esophageal injury. Morden NE; Munson JC; Smith J; Mackenzie TA; Liu SK; Tosteson AN Osteoporos Int; 2015 Feb; 26(2):663-72. PubMed ID: 25349053 [TBL] [Abstract][Full Text] [Related]
32. Bisphosphonates and risk of upper gastrointestinal cancer--a case control study using the General Practice Research Database (GPRD). Wright E; Schofield PT; Seed P; Molokhia M PLoS One; 2012; 7(10):e47616. PubMed ID: 23112825 [TBL] [Abstract][Full Text] [Related]
33. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. Lee J; Youn K; Choi NK; Lee JH; Kang D; Song HJ; Park BJ J Gastroenterol; 2013 Sep; 48(9):1016-22. PubMed ID: 23307040 [TBL] [Abstract][Full Text] [Related]
34. Bisphosphonate Use and the Risk of Undergoing Total Knee Arthroplasty in Osteoporotic Patients with Osteoarthritis: A Nationwide Cohort Study in Taiwan. Fu SH; Wang CY; Yang RS; Wu FL; Hsiao FY J Bone Joint Surg Am; 2017 Jun; 99(11):938-946. PubMed ID: 28590379 [TBL] [Abstract][Full Text] [Related]
35. Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis. Rhee CW; Lee J; Oh S; Choi NK; Park BJ Osteoporos Int; 2012 Jan; 23(1):247-54. PubMed ID: 21431993 [TBL] [Abstract][Full Text] [Related]
36. Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models. Zambon A; Baio G; Mazzaglia G; Merlino L; Corrao G Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):260-9. PubMed ID: 18240162 [TBL] [Abstract][Full Text] [Related]
37. Postoperative use of bisphosphonates and risk of revision after primary total hip arthroplasty: a nationwide population-based study. Thillemann TM; Pedersen AB; Mehnert F; Johnsen SP; Søballe K Bone; 2010 Apr; 46(4):946-51. PubMed ID: 20102756 [TBL] [Abstract][Full Text] [Related]
38. Heart failure in patients treated with bisphosphonates. Grove EL; Abrahamsen B; Vestergaard P J Intern Med; 2013 Oct; 274(4):342-50. PubMed ID: 23679231 [TBL] [Abstract][Full Text] [Related]
39. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Loke YK; Jeevanantham V; Singh S Drug Saf; 2009; 32(3):219-28. PubMed ID: 19338379 [TBL] [Abstract][Full Text] [Related]
40. Meta-analysis: oral bisphosphonates and the risk of oesophageal cancer. Andrici J; Tio M; Eslick GD Aliment Pharmacol Ther; 2012 Oct; 36(8):708-16. PubMed ID: 22966908 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]